News

PipelineReview.com1h
LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases
REDWOOD CITY, CA, USA & SHENZHEN, China I July 29, 2025 I LTZ Therapeutics (“LTZ”), an immunotherapy-focused biotechnology company, today announced a ...
PipelineReview.com1h
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
LAVAL, Canada and CUPERTINO, CA, USA I July 29, 2025 I Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and ...
PipelineReview.com1h
Formation Bio Licenses First-in-Class Anti-CD226 Autoimmune Program from IMIDomics
The anti-CD226 mAb adds to Formation Bio’s growing pipeline which currently includes programs in immunology, dermatology, and rheumatology and reflects the company’s focus on first- and best-in-class ...